1 active not recruiting, 1 completed, 1 not yet recruiting, 1 temporarily not available. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Immunis, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia IMM02-KORA - Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced | Phase 1 | Not yet recruiting | Immunis, Inc. | 15 | 2026-11-30 | 2026-10-30 |
| Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline) - Muscle Performance, Sarcopenic Obesity | Phase 2 | Active not recruiting | Immunis, Inc. | 55 | 2024-12-19 | 2026-01-29 |
| Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. IMM01-STEM - Muscle Atrophy | Phase 1 / Phase 2 | Completed | Immunis, Inc. | 13 | 2022-09-13 | 2026-09-09 |
| INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY IMM01-STEM - Sarcopenia, Obesity and Obesity-related Medical Conditions | Temporarily not available | Immunis, Inc. | 2026-03-06 |
Dyskinesia, Drug-Induced (1) · Dyskinesias (1) · Muscular Atrophy (1) · Obesity (1) · Sarcopenia (1)
Sodium Chloride (1) · TRK 820 (1)
United States (2)
Tom Lane, PhD (2) · Mani Nistor (1)